Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alnylam Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alnylam Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer | 95,802 | Sep 22, 2026 | 9 |
| Pyott David E I | Director | 1,582 | Jun 3, 2026 | 2 |
| Cravatt Benjamin | Director | – | Jun 3, 2026 | 1 |
| Kellogg Peter N | Director | 1,446 | May 22, 2026 | 1 |
| Hamburg Margaret A | Director | 1,582 | May 22, 2026 | 1 |
| Ausiello Dennis A | Director | 1,582 | May 22, 2026 | 1 |
| Schulman Amy W | Director | 24,049 | May 22, 2026 | 2 |
| Brandicourt Olivier | Director | 1,446 | May 22, 2026 | 1 |
| Arbuckle Stuart A | Director | 671 | May 22, 2026 | 2 |
| Sigal Charles Elliott | Director | 1,446 | May 22, 2026 | 1 |
| Reitan Colleen F | Director | 1,446 | May 22, 2026 | 1 |
| McLaughlin Melissa | Chief Human Resources Officer | 9,443 | Apr 7, 2026 | 1 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 61,805 | Mar 6, 2026 | 6 |
| Garg Pushkal | EVP Chief R&D | 18,693 | Mar 6, 2026 | 6 |
| Tanguler Tolga | EVP, Chief Commercial Officer | 34,297 | Mar 6, 2026 | 6 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 20,569 | Mar 6, 2026 | 7 |
| Supran Bryan | EVP, CLO and Secretary | 14,565 | Mar 4, 2026 | 2 |
| Bonney Michael W | Director | 16,804 | Aug 19, 2025 | 0 |
| Bertozzi Carolyn R | Director | 775 | May 12, 2025 | 0 |
| Hesslein Robert W. | EVP, CLO and Secretary | 8,002 | Mar 5, 2025 | 0 |
| Sharp Phillip A | Director | 0 | Jan 24, 2025 | 0 |
| Franchini Indrani Lall | EVP, CLO & Secretary | 4,133 | Feb 29, 2024 | 0 |
| Vaishnaw Akshay | President | 22,774 | Aug 7, 2023 | 0 |
| Fanucci Marsha | Director | 136 | May 19, 2023 | 0 |
| Paul Steven M | Director | 1,000 | Apr 5, 2022 | 0 |
| Maraganore John | Chief Executive Officer | 227,663 | Dec 23, 2021 | 0 |
| Keating Laurie | EVP, Chief Legal Officer | 5,132 | Aug 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 (view filing) | Apr 27 | 1 day | Vaishnaw AkshayPresident | SSale | −2.39K | $194.59 | −$465.5K | −11.8%17.9K after | 5 lots |
| Apr 28, 2023 (view filing) | Apr 27-28 | 1 day | Garg PushkalCMO & EVP Dev & Med Affairs | SSale | −4.29K | $197.12 | −$846.4K | −49.7%4.34K after | 11 lots |
| Apr 10, 2023 (view filing) | Apr 6 | 4 days | Franchini Indrani LallEVP, CLO & Secretary | SSale | −3.50K | $210.00 | −$735.0K | −100.0%0 after | |
| Mar 7, 2023 (view filing) | Mar 3 | 4 days | Garg PushkalCMO & EVP Dev & Med Affairs | SSale | −18.1K | $200.00 | −$3.61M | −80.6%4.34K after | |
| Feb 14, 2023 (view filing) | Feb 10 | 4 days | Vaishnaw AkshayPresident | SSale | −38.0K | $215.97 | −$8.22M | −71.8%15.0K after | 5 lots |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | Franchini Indrani LallEVP, CLO & Secretary | SSale | −1.68K | $226.01 | −$378.6K | −32.4%3.50K after | 4 lots |
| Feb 3, 2023 (view filing) | Feb 2-3 | 1 day | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −5.03K | $230.19 | −$1.16M | −100.0%0 after | 9 lots |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Ausiello Dennis ADirector | SSale | −22.5K | $220.00 | −$4.95M | −100.0%0 after | |
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | Sharp Phillip ADirector | SSale | −33.7K | $230.49 | −$7.76M | −100.0%0 after | 6 lots |
| Aug 5, 2022 (view filing) | Aug 3-5 | 2 days | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −3.60K | $214.18 | −$770.0K | −100.0%0 after | 9 lots |
| Jul 7, 2022 (view filing) | Jul 5 | 2 days | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −1.75K | $150.00 | −$263.1K | −50.0%1.75K after | |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Paul Steven MDirector | SSale | −15.0K | $170.69 | −$2.56M | −93.8%1.00K after | 10 lots |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Sharp Phillip ADirector | SSale | −30.0K | $150.00 | −$4.50M | −100.0%0 after | |
| Dec 23, 2021 (view filing) | Dec 23 | Same day | Vaishnaw AkshayPresident, R&D | SSale | −2.88K | $190.93 | −$549.7K | −20.4%11.2K after | 17 lots |
| Nov 12, 2021 (view filing) | Nov 12 | Same day | Maraganore JohnChief Executive Officer | SSale | −34.0K | $171.52 | −$5.83M | −13.7%214.8K after | 5 lots |
| Aug 16, 2021 (view filing) | Aug 13 | 3 days | Maraganore JohnChief Executive Officer | SSale | −34.0K | $199.78 | −$6.79M | −13.7%214.8K after | 5 lots |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Vaishnaw AkshayPresident, R&D | SSale | −10.8K | $200.00 | −$2.17M | −49.1%11.2K after | |
| Aug 9, 2021 (view filing) | Aug 5 | 4 days | Keating LaurieEVP, Chief Legal Officer | SSale | −10.0K | $188.95 | −$1.89M | −66.1%5.13K after | |
| Aug 9, 2021 (view filing) | Aug 6 | 3 days | Greenstreet YvonnePresident & COO | SSale | −53.1K | $199.00 | −$10.6M | −82.8%11.0K after | |
| Jul 14, 2021 (view filing) | Jul 12 | 2 days | Keating LaurieEVP, Chief Legal Officer | SSale | −6.81K | $178.96 | −$1.22M | −57.0%5.13K after | 2 lots |